Table D44. Other subgroup outcome 2

| Author, Year  Trial Name | Subgroup | Outcome 2 for Subgroup | Description of Timing of Measurement of Outcome | Data source | N | Results |
| --- | --- | --- | --- | --- | --- | --- |
| Bogner et al., 20084 NA | Depression and hypertension | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |
| Bogner et al., 20105 NA | African American primary care patients | A1C/Blood glycemic control | 2 times, at baseline and 12 weeks | A1C assays | G1: 29 G2: 29 | **BL (%)** G1: Mean (SD) = 7.3 (2.3) G2: Mean (SD) = 7.3 (2.0) 95% CI, NR p: 0.70 **EP (%)** G1: Mean (SD) = 6.7 (2.3) G2: Mean (SD) = 7.9 (2.6) 95% CI, NR p: 0.019 |
| Fulmer et al., 199915 NA | Elderly | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |
| Katon et al., 199524 NA | Major depression | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |
| Katon et al., 199625 NA | Major depression | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |
| Katon et al., 199926 NA  Katon et al., 200227 NA | Severe depression at baseline  (Reported in 3169) | Depression severity and functional impairment in patients with Severe depression at baseline | Measured at 1, 3, 6, and 28 months; analysis at 28 months | SCL Depression scale (for depression severity); Sheehan disability score (for functional impairment) | G1: NR G2: NR | Depression severity: ANCOVA: F(1.51)=0.02 Adjusted mean, (SD): G1: 1.16, (0.85) G2: 1.19, (0.72) p: 0.88  Sheehan disability score: ANCOVA: F(1.51) = 0.09 Adjusted mean, (SD): G1: 3.41, (2.61) G2: 3.20, (2.66) p: 0.76 |
| Lee et al. (continued), 200631 FAME | Patients with drug-treated hyperlipidemia | Drug-treated hyperlipidemia patients only: LDL-C at 14 months, mean (SD) | At 14 months; 1 time measure for this outcome | Direct assay measurement | G1: 64 G2: 57 | G1: 87.5 (24.2) G2: 88.4 (21.0) 95% CI, NR  p: 0.84 |
| Lee et al., 200631 FAME | Patients with drug-treated hypertension | Drug treated hypertension patients only: Difference in Systolic BP at 14 months (95% CI) | Difference between SBP values at 14 months and at 2 months; frequency = 2 measurements; duration between measures = 12 months | Clinical pharmacist measurement | G1: 73 G2: 62 | G1: -6.9  (-10.7 to -3.1) G2: -1.0  (-5.9 to 3.9) 95% CI,NR  p: 0.04 |
| Lin et al., 200632 NA | Depression and diabetes | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |
| Rich et al., 199642 NA | Elderly (≥70 years of age) | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |
| Schneider et al., 200849 NA | Elderly, i.e., ≥65 years of age (entire sample) | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction | See main outcomes abstraction |